Daix (France), Long Island City (New York), United States, January 31, 2022 – Inventiva SA (“Inventiva” or the “Company”) (Euronext Paris and Nasdaq: IVA), a biopharmaceutical company specializing in the clinical development Oral Small Molecules for the Treatment of Non-Alcoholic Steatohepatitis (NASH), Mucopolysaccharidosis (MPS) and Other Diseases with Significant Unmet Medical Need, Announces Today Received Milestone Payment 4 million euros from AbbVie. This follows the inclusion of the first patient with psoriasis in the ongoing Phase IIb clinical study with cedirogant (ABBV-157), an oral RORy inverse agonist jointly discovered by Inventiva and AbbVie for the treatment of autoimmune diseases.